Westwood, KSNCT03533816Now EnrollingIRB Ready

Acute Myeloid Leukemia Clinical Trial in Westwood, KS

Access cutting-edge acute myeloid leukemia treatment through this clinical trial at a research site in Westwood. Study-provided care at no cost to qualified participants.

Sponsored by University of Kansas Medical Center

Quick Self-Assessment

See if you qualify for this Westwood location

Preparing your pre-screening questions…

Expert Care in Westwood

Access acute myeloid leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute myeloid leukemia treatment provided free

Apply for This Westwood Location

Check if you qualify for this acute myeloid leukemia clinical trial in Westwood, KS

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Westwood

    Convenient for KS residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Westwood site if eligible
  4. 4Begin participation

About This Acute Myeloid Leukemia Study in Westwood

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).

Sponsor: University of Kansas Medical Center

Who Can Participate

Inclusion Criteria

The following criteria are used to enroll patients in the study before transplant.
Patients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (NCCN) or other standard guidelines as follows:
Acute myeloid leukemia \[AML\] in morphologic complete remission with intermediate/high-risk features (per NCCN criteria) or relapsed disease
Chronic myeloid leukemia \[CML\] in any chronic phase.
Myelodysplastic syndrome \[MDS\] with intermediate/high risk features or refractory disease (with bone marrow blast count \<10%).
Acute lymphoblastic leukemia \[ALL\] in morphologic complete remission with high-risk features or relapsed disease.
Negative test for donor-specific antibody within 28 days of starting conditioning regimen.
Age Criteria: 19-65 years.
Organ Function Criteria: The following organ function testing should be done within 35 days before study registration.
Cardiac: Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram.
Pulmonary: FVC, FEV1 and DLCO (corrected) should be 50% or above of expected.
Renal: serum creatinine level to be \<2 mg/dl AND estimated (Cockcroft-Gault formula) or measured (takes priority if done) creatinine clearance (CrCl) must be equal or greater than 70 mL/min/1.73 m2.
Hepatic: serum bilirubin 1.5 upper limit of normal (ULN), Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN, and alkaline phosphatase 2.5 ULN.
Performance status: Karnofsky performance score (KPS) or Lansky score: ≥80.
Hematopoietic cell transplant comorbidity index (HCT-CI) \<3. Exception may be made on individual cases after discussion with the primary investigator.
Consent: All patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines. The following criteria are required within 48 hours prior to infusion of the EAGD T cell product.
Absence of uncontrolled infection with sepsis syndrome (e.g persistent positive blood culture).
NO hemodynamic instability (due to sepsis or organ dysfunction) or circulatory volume overload.
NO clinically significant organ toxicity that are defined as follows:
Heart failure with subnormal LVEF or clinical fluid overload.
Elevated serum creatinine or subnormal creatinine clearance (either estimated or measured).
Elevated total bilirubin ≥1.5 upper normal level (unless indirect hyperbilirubinemia attributed to non-hepatic pathology), or elevated liver enzymes (ALT, AST, ALP) \>5 x ULN.
Hypoxemia requiring oxygen therapy
NO acute graft versus host disease (any grade).
Neutrophil engraftment.

Exclusion Criteria

Non-compliant patients.
No appropriate caregivers identified.
Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).
Active central nervous system (CNS) neoplastic involvement.
Morbid obesity with body mass index \>35 (borderline cases may be considered on case-by-case basis after discussion with the primary investigator).
Patients with known allergy to DMSO.
HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive.
Pregnant or breastfeeding women.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Westwood?

Yes, this clinical trial (NCT03533816) has an active research site in Westwood, KS that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Myeloid Leukemia Treatment Options in Westwood, KS

If you're searching for acute myeloid leukemia treatment options in Westwood, KS, this clinical trial (NCT03533816) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Westwood research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute myeloid leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Westwood, KS

See all leukemia clinical trials recruiting in Westwood — not just this study.

Browse Leukemia Trials in Westwood →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsHeart Attack TrialsMyocardial Infarction TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Westwood?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Westwood, KS